QCG
ZNTL icon

Quadrant Capital Group’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Quadrant Capital Group’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-24
Closed -$99 – 2796
2024
Q2 		$99 Buy
+24
New +$268 ﹤0.01% 2687
2023
Q2 		– Sell
-89
Closed -$1.53K – 2782
2023
Q1 		$1.53K Hold
89
– – ﹤0.01% 2474
2022
Q4 		$1.79K Buy
+89
New +$1.91K ﹤0.01% 2444

Other funds holding ZNTL

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Quadrant Capital Group's ZNTL Position: Q3 2024 in Review

Quadrant Capital Group sold out of Zentalis Pharmaceuticals (ZNTL) in Q3 2024, closing a stake of 24 shares — an estimated $99 sold.

Quadrant Capital Group first reported a position in ZNTL in Q4 2022 and held it in 3 quarters. The position peaked at $1.79K in Q4 2022. 136 funds tracked by Wall St. Rank hold ZNTL as of Q3 2024.

  • Quadrant Capital Group reported no remaining Zentalis Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Quadrant Capital Group sold 24 Zentalis Pharmaceuticals shares in Q3 2024, an estimated $99.
  • Quadrant Capital Group first reported a position in Zentalis Pharmaceuticals in Q4 2022 and held it in 3 quarters.
  • Quadrant Capital Group's Zentalis Pharmaceuticals position peaked at $1.79K in Q4 2022.
  • 136 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q3 2024.

Based on Quadrant Capital Group's 13F filing for Q3 2024, filed 12 Nov 2024.